[EFFECT] Nasus Pharma Ltd SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

04/01/2026 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	March 31, 2026

Accession Number:

0001493152-26-013287

Submission Type:

POS AM

CIK:	0002029039
Company Name:	Nasus Pharma Ltd
File Number:	333-293950

Source: View Original Filing on SEC EDGAR

Nasus Pharma Ltd.

NYSE:NSRX

View NSRX Stock Overview →

NSRX Rankings

#5996 Ranked by Market Cap

N/A Ranked by Dividends

NSRX Latest News

Mar 25, 2026

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Mar 16, 2026

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

Mar 9, 2026

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Mar 9, 2026

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Feb 20, 2026

Nasus Pharma to Participate in Upcoming Investor Conferences

NSRX Latest SEC Filings

Apr 1, 2026

[Form 4] Nasus Pharma Ltd Insider Trading Activity

Mar 27, 2026

[POS AM] Nasus Pharma Ltd SEC Filing

Mar 27, 2026

[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership

Mar 27, 2026

[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership

Mar 27, 2026

[Form 3] Nasus Pharma Ltd Initial Statement of Beneficial Ownership

NSRX Stock Data

Market Cap 26.00M

Float 5.85M

Industry Drug Manufacturers - General

Sector Healthcare

Website Link

Country Israel

City Tel Aviv-Yafo